Advertisement

The changing landscape of systemic therapy in the treatment of synchronous metastatic hormone-sensitive prostate cancer

Published:November 13, 2022DOI:https://doi.org/10.1016/j.clgc.2022.11.001

      ABSTRACT

      Introduction

      To describe the changes in systemic treatments (ST) of synchronous metastatic hormone-sensitive prostate cancer (mHSPC) patients in a “real-world” setting and to explore reasons why contemporary standard of care (SOC) was not administrated to the patient.

      Patients and methods

      Since 2014, we prospectively register mHSPCpatients. Patients were grouped in 4 time periods: group 1 (Time period 1, January 2014-July 2015), group 2 after introduction of docetaxel (Time period 2, August 2015-July 2017), group 3 after introduction of abiraterone acetate (Time period 3, August 2017-February 2018) and group 4 after introduction of apalutamide (Time period 4, March 2018-October 2021). For every time period, we evaluated the initiated additional ST. In case patients received treatment that differed from contemporary SOC according to guidelines, reasons for this difference were explored.

      Results

      In total, 243 patients were included. A progressive decline in ADT monotherapy from 85% to 29% over time was observed. The proportion of patients receiving additional STs increased from 34% to 59%. Fourty percent of patients were not treated according to contemporary SOC, but this percentage varied strongly per time period (10%, 67%, 53% and 32% from time period 1 to time period 4 respectively). Reasons for these variations were heterogenous and varied across the 4 time periods. Patients being unfit for treatment and treating physicians failing to consider additional STs were the most prevalent reasons. The proportion of patients unfit for additional ST decreased from 18% to 4% over time.

      Conclusion

      Use of ADT monotherapy declined gradually after the introduction of additional systemic treatments. The proportion of patients unfit for additional ST declined as more treatments became available. Although compliance to SOC increased over time, these real-world data show that adherence to clinical practice guidelines remains suboptimal. Efforts should be made by clinicians to increase the adherence to practice guidelines.
      MICROABSTRACT
      In the last decade, a shift has occurred in the treatment of patients with newly diagnosed metastatic prostate cancer (ndMPC) from ADT monotherapy to early combination therapies of ADT with docetaxel or ARTAs. Although the introduction of novel systemic therapies has made more patients eligible for additional treatments, adherence to clinical practice guidelines remains suboptimal.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • James ND
        • Spears MR
        • Clarke NW
        • Dearnaley DP
        • De Bono JS
        • Gale J
        • et al.
        Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
        Eur Urol. 2015 Jun; 67: 1028-1038
        • Pagliarulo V
        • Bracarda S
        • Eisenberger MA
        • Mottet N
        • Schröder FH
        • Sternberg CN
        • et al.
        Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer.
        Eur Urol. 2012 Jan; 61: 11-25
        • Nuhn P
        • De Bono JS
        • Fizazi K
        • Freedland SJ
        • Grilli M
        • Kantoff PW
        • et al.
        Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
        Eur Urol. 2019 Jan; 75: 88-99
        • Sweeney CJ
        • Chen Y-H
        • Carducci M
        • Liu G
        • Jarrard DF
        • Eisenberger M
        • et al.
        Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
        N Engl J Med. 2015 Aug 20; 373: 737-746
        • Fizazi K
        • Tran N
        • Fein L
        • Matsubara N
        • Rodriguez-Antolin A
        • Alekseev BY
        • et al.
        Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
        N Engl J Med. 2017 Jul 27; 377: 352-360
        • Chi KN
        • Agarwal N
        • Bjartell A
        • Chung BH
        • Pereira de Santana Gomes AJ
        • Given R
        • et al.
        Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
        N Engl J Med. 2019 Jul 4; 381: 13-24
        • Davis ID
        • Martin AJ
        • Stockler MR
        • Begbie S
        • Chi KN
        • Chowdhury S
        • et al.
        Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
        N Engl J Med. 2019; 381: 121-131
        • Smith MR
        • Saad F
        • Hussain M
        • Sternberg CN
        • Fizazi K
        • Yamada KS
        • et al.
        ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).
        J Clin Oncol. 2018 Feb 20; 36 (_suppl–TPS383): TPS383
        • Mottet N
        • Bellmunt J
        • Briers E
        • den Bergh RCN van
        • Bolla M
        • van Casteren NJ
        • et al.
        EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer.
        Update. 2020;
        • Cornford P
        • Smith EJ
        • MacLennan S
        • Pereira-Azevedo N
        • Roobol MJ
        • Lumen N
        • et al.
        IMAGINE—IMpact Assessment of Guidelines Implementation and Education: The Next Frontier for Harmonising Urological Practice Across Europe by Improving Adherence to Guidelines.
        Eur Urol. 2021 Feb; 79: 173-176
        • Freedland SJ
        • Sandin R
        • Sah J
        • Emir B
        • Mu Q
        • Ratiu A
        • et al.
        Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration.
        Cancer Med. 2021 Dec 2; 10: 8570-8580
        • Epstein JI
        • Egevad L
        • Amin MB
        • Delahunt B
        • Srigley JR
        • Humphrey PA.
        The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
        Am J Surg Pathol. 2016 Feb; 40: 244-252
        • Lambert E
        • Hollebosch S
        • van Praet C
        • Van Bruwaene S
        • Duck L
        • De Roock W
        • et al.
        Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
        Acta Clin Belg. 2021 Nov 18; : 1-9
        • Heidenreich A
        • Bastian PJ
        • Bellmunt J
        • Bolla M
        • Joniau S
        • van der Kwast T
        • et al.
        EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer.
        Eur Urol. 2014 Feb; 65: 467-479
        • James ND
        • De Bono JS
        • Spears MR
        • Clarke NW
        • Mason MD
        • Dearnaley DP
        • et al.
        Abiraterone for prostate cancer not previously treated with hormone therapy.
        N Engl J Med. 2017; 377: 338-351
        • Armstrong AJ
        • Szmulewitz RZ
        • Petrylak DP
        • Holzbeierlein J
        • Villers A
        • Azad A
        • et al.
        ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
        J Clin Oncol. 2019 Nov 10; 37: 2974-2986
        • James ND
        • Sydes MR
        • Clarke NW
        • Mason MD
        • Dearnaley DP
        • Spears MR
        • et al.
        Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
        Lancet. 2016; 387: 1163-1177
        • Lowrance WT
        • Breau RH
        • Chou R
        • Chapin BF
        • Crispino T
        • Dreicer R
        • et al.
        Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
        J Urol. 2021 Jan; 205: 14-21
        • Cornford P
        • van den Bergh RCN
        • Briers E
        • Van den Broeck T
        • Cumberbatch MG
        • De Santis M
        • et al.
        EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
        Eur Urol. 2021 Feb; 79: 263-282
        • Schaeffer E
        • Srinivas S
        • Antonarakis ES
        • Armstrong AJ
        • Bekelman JE
        • Cheng H
        • et al.
        NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
        J Natl Compr Cancer Netw. 2021 Feb; 19: 134-143
        • Hussain M
        • Tangen CM
        • Higano C
        • Schelhammer PF
        • Faulkner J
        • Crawford ED
        • et al.
        Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162).
        J Clin Oncol. 2006 Aug 20; 24: 3984-3990
        • Fizazi K
        • Maldonado X
        • Foulon S
        • Roubaud G
        • McDermott RS
        • Flechon A
        • et al.
        A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
        J Clin Oncol. 2021 May 20; 39 (_suppl–5000): 5000
        • Parker CC
        • James ND
        • Brawley CD
        • Clarke NW
        • Hoyle AP
        • Ali A
        • et al.
        Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
        Lancet. 2018;
        • Buelens S
        • Poelaert F
        • Claeys T
        • De Bleser E
        • Dhondt B
        • Verla W
        • et al.
        Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study).
        BJU Int. 2021 Jul 21; : bju.15553
        • Ryan CJ
        • Ke X
        • Lafeuille M-H
        • Romdhani H
        • Kinkead F
        • Lefebvre P
        • et al.
        Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.
        J Urol. 2021 Dec; 206: 1420-1429
        • Ke X
        • Lafeuille M-H
        • Romdhani H
        • Kinkead F
        • Francis PSJ
        • D'Andrea D
        • et al.
        Treatment patterns in men with metastatic castration sensitive prostate cancer (mCSPC) in the United States (US).
        J Clin Oncol. 2020 May 20; 38 (_suppl–e19131): e19131
        • Flaig TW
        • Potluri RC
        • Ng Y
        • Todd MB
        • Mehra M
        • Higano CS.
        Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database.
        Clin Genitourin Cancer. 2017 Apr; 15 (e1): 273-279